Latest News-Beijing Jiakesi New Drug Development Co., Ltd. Mediaroom_Page

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

BEIJING, SHANGHAI and BOSTON, Dec. 1, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present th...

2022-12-02 08:30 1549

Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a...

2022-10-13 09:00 1956

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

BEIJING, SHANGHAI and BOSTON, Sept. 6, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) has received P...

2022-09-06 15:20 1820

Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China

BEIJING, Sept. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed first pa...

2022-09-02 19:00 2430

Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China

BEIJING, Sept. 1, 2022 /PRNewswire/ -- JacobioPharma (1167.HK) announced that the company has dosed...

2022-09-02 17:14 2108

Jacobio Pharma Announces 2022 Interim Results

Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million. Globa...

2022-08-24 00:32 3081

Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to a...

2022-05-28 00:22 6168

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%

BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual r...

2022-03-22 22:50 2292

Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) annou...

2022-02-24 10:32 1654

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global firs...

2022-01-17 09:04 1426

Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received...

2021-12-06 09:16 2300

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", ...

2021-08-31 22:05 3829

Jacobio Pharmaceuticals Announces 2021 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", ...

2021-08-31 22:01 4689

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor

BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first p...

2021-08-03 09:00 3261

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment

BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) ha...

2021-06-18 08:31 3618

Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor

BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has ...

2021-05-03 09:30 3940

Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results

BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its ...

2021-03-29 13:11 3531